SUMMARY Disopyramide phosphate was administered intravenously in a dose of 1-2 mg/kg body weight over one minute to nine patients after open-heart surgery and coronary artery bypass grafting. The haemodynamic changes were studied during and for 30 minutes after drug administration. Heart rate was unchanged throughout the study. During infusion the only significant changes were an increase in systemic blood pressure and systolic impedance signifying a direct increase in peripheral arterial resistance. Systemic blood pressure remained significantly higher for 10 minutes and systolic impedance for 30 minutes. Immediately after infusion max. dPower/dT, a measure of ventricular contractility, was significantly depressed for 15 minutes. Both cardiac output and aortic flow were significantly depressed for 30 minutes. DPTI/TTI, an estimate of subendocardial supply/demand ratio, showed an insignificant increase throughout the study.
Disopyramide (4 diisopropylamino-2-phenyl-2-(2-pyridyl) butyramide) has proved to be an effective new antiarrhythmic drug. Its efficacy in suppressing ventricular arrhythmias (Vismara et al., 1974; Mizgala and Huvelle, 1976; Deano et al., 1977) and, to a lesser extent, supraventricular arrhythmias (Lerch, 1976; Daly and Owens, 1977; Ward et al., 1977 ) is well documented. Electrophysiological studies have shown a beneficial effect in WolffParkinson-White syndrome (Spurrell et al., 1975; Camm and Spurrell, 1977) . It has been shown to be effective in the prophylaxis and treatment of arrhythmias occurring after myocardial infarction (Hillis et al., 1976; Jennings et al., 1976) .
The haemodynamic effects of disopyramide phosphate (Norpace:Searle) given intravenously to nine patients after open-heart surgery and coronary artery bypass grafting are reported. The particular aims of the study were to measure the time of onset of action of disopyramide and the early haemodynamic changes after intravenous injection.
Subjects and methods
Nine patients with ischaemic heart disease underReceived for publication 21 May 1979 going coronary artery bypass grafting were recruited to the study. Prior informed consent was obtained.
Exclusion criteria included the following: (1) Patients who had received digitalis glycosides within two weeks before the study. (4) Patients suffering from urinary retention (Large and Todd, 1977) or glaucoma (Trope and Hind, 1978) . (5) Patients with renal failure (Whiting and Elliott, 1977; Whiting and Miller, 1977) . (6) Patients receiving any anticholinergic drug. (7) Patients with atrioventricular or severe intraventricular conduction defects (Niarchos, 1976; Croxson and Atkin, 1977) . (8) Patients with congestive cardiac failure. (9) Patients who had a known sensitivity to disopyramide phosphate. Before closure of the chest after the placement of the bypass grafts a rigid non-cannulating extractable electromagnetic blood flow probe (Carolina Medical Electronics 900 series) with suitable internal circumference was applied to the ascending aorta as previously described (Williams et al., 1972; Farnsworth et al., 1977) . Details of the use of such a flow probe to assess myocardial performance in man are published elsewhere (Lewis et al., 1978) . The connections of the flow probe, and the monitoring equipment used in the study are detailed by Malcolm et al. (1977) (Bourne and Williams, 1975 drug assay. Three to five control readings were taken, each at five-minute intervals. If the control readings were comparable, disopyramide phosphate (Norpace:Searle) was given intravenously in a dose of 1-2 mg/kg body weight over a period of one minute. Readings were started at the beginning of the infusion and continued throughout the infusion to enable the time of onset of action of the drug to be measured. Thereafter readings were taken at one-minute intervals for 10 minutes and then at five-minute intervals for the next 20 minutes. 10 ml venous blood were withdrawn for drug assay at five, 10, 15, 20, and 30 minutes into heparinised tubes. These samples were centrifuged within a few minutes of collection and the plasma stored at -20°C for subsequent drug assay. Student's t test for paired samples was used to determine the significance of changes from preinfusion values, each patient acting as his own control. Values are expressed as mean ± standard error of the mean, and a P value < 0-05 is considered significant.
The clinical details of the patients studied are given in the Table. Results There was no significant change in heart rate or duration of systole. The mean heart rate at one minute had increased by 4-9 per cent but this was not statistically significant. Thereafter there was no change in heart rate. At 30 minutes the mean heart rate had decreased by an insignificant 1-8 per cent.
The changes in mean blood pressure are shown in Fig. 1 minute after the onset of infusion. At five minutes the increase was much less and was not significant for the systolic pressure. The increase in diastolic and mean pressure remained highly significant for up to 10 minutes. The percentage increase in the systolic, mean, and diastolic pressures at one minute were 16, 22, and 28, respectively. After 10 minutes the increase in mean pressure was not statistically significant. The immediate rise in pressures was followed by an initial rapid and then gradual fall towards control values though the latter were not reached even at 30 minutes. The mean pressure at 30 minutes was 5-2 per cent greater than control values.
Changes in maximum flow are recorded in Fig. 2 . Mean systolic impedance, shown in Fig. 3 , increased strikingly and this increase remained statistically significant throughout the study, the maximum increase occurring at one minute after the onset of drug infusion and the mean increase being of the magnitude of 35 per cent compared with control values. Again a gradual drift towards control values occurred, but at 30 minutes was still increased by 14-5 per cent. Impedance at maximum flow remained significantly raised throughout the study after the drug infusion. Max. dPower/dT, a measure of ventricular contractility (Stein and Sabbah, 1976) , was initially depressed after drug infusion but by 30 minutes had returned almost completely to control values (Fig. 4) . The difference was not statistically significant after 15 minutes. The percentage change from control values was 12, 13-5, 8-4, 8 4 at one, five, 10, and 15 minutes, respectively.
Cardiac output was reduced after drug infusion (Fig. 5) . This reduction was greatest (13-3%) at one minute and remained significantly depressed for 30 minutes. By 30 minutes the mean depression was 8-6 per cent. As expected, changes in stroke volume merely reflected the changes in cardiac output since there was no significant change in heart rate. Although maximum LV ejection power showed an initial depression after drug infusion, this was not statistically significant. The changes in mean LV ejection power were inconstant and were not statistically significant. There was no statistically significant change in stroke work.
The ratio DPTI/TTI, which is an estimate of subendocardial supply/demand relation (Buckberg et al., 1972; Hoffnan and Buckberg, 1978) , is shown in Fig. 6 . At one minute after the start of 5. 4. w 3.
> 2-to drug infusion there was a 45 per cent increase but this was not statistically significant. Thereafter the increase remained steady at around 4 per cent.
Changes occurring during drug administration were monitored in seven patients. There was no significant change in any of the values during the first 30 seconds. The changes that occurred between 30 and 50 seconds after the start of drug infusion are shown in Fig. 7 . The increase in mean pressure and mean systolic impedance was significant (P < 0 05), the percentage change being 10-3 and 17, respectively. There was no significant change in cardiac output and max. dPower/dT at this time.
There was no change in left atrial or right atrial pressure at any stage after drug administration.
The blood levels of disopyramide, determined by the method of Hutsell and Stachelski (1975) , are given in Fig. 8 .
Discussion
Before discussing the haemodynamic effects of disopyramide certain facts need to be clarified. We believe, like Slogoffet al. (1977) , that continued treatment with beta-blocking drugs before openheart surgery is beneficial and hence continue betablockade until the time of surgery. Some negative inotropic effect from these drugs will inevitably be present for some time during the postoperative period. Jenkins et al. (1973) have claimed that it is possible that the period of cardiopulmonary bypass is a further contributory factor to myocardial depression immediately after surgery regardless of previous cardiac pathology, and in the majority of patients studied by them the ventricular function curves were relatively flat. Hence, in our patients some depression of myocardial function may well have been present before disopyramide was administered. However, our study is particularly relevant since this is just the situation in which disopyramide is often used, that is after open-heart surgery, after myocardial infarction complicated by arrhythmias, etc.-situations where myocardial depression is often an important factor.
The other point to be noted is that the dose of disopyramide used in this study was fairly modest. However, the plasma levels of the drug were within the accepted therapeutically effective range which is between 2 and 4 1±g/ml (Karim, 1975; Rangno et al., 1976) . The fact that the drug was given over one minute and not longer could well have contributed to the extent of the changes seen at the one-minute period.
In animal experiments disopyramide has been shown to have a weak negative inotropic effect (Mokler and Van Arman, 1962; Mathur, 1972;  found that intravenous disopyramide reduced cardiac output by 9 to 22 per cent, depressed cardiac contractility, reduced coronary flow, and produced only small inconstant changes in heart rate. Changes in systemic blood pressure after disopyramide administration have varied in different series. The variability is probably attributable to differences in left ventricular function of the patients studied. A fall in blood pressure was found by Jensen et al. (1975) in patients who had imminent or manifest heart failure, and by Sutton (1976) in patients with abnormal left ventricular function. Hulting and Rosenhamer (1975) found no significant change in mean arterial pressure measured five and 10 minutes after drug administration, but from the twentieth minute to the end of the observation period (180 minutes) mean arterial pressure was significantly increased above control values. Befeler (1975) and Marrot et al. (1976) have reported a rise in blood pressure after disopyramide administration. We found an immediate rise in systolic, diastolic, and mean pressure which was maximal at one minute, and these pressures, though returning towards control values, remained raised throughout the study. At five minutes the rise in blood pressure was only marginally more than that in Marrot et al.'s study (1976)-7, 14, and 11-7 per cent compared with 7, 10, and 7 per cent in systolic, diastolic, and mean blood pressures, respectively. Initially it was thought that the increase in blood pressure was a reflex response to the lowering of cardiac output (Befeler, 1975) . However, during infusion of the drug there was a significant rise in mean pressure and mean systolic impedance (Fig. 7) . There was no decrease in rate of change of power and the change in cardiac output was not significant. Hence the significant early change in systemic pressure and systolic impedance but not in cardiac output and max. dPower/dT suggested that the increase in blood pressure was not a reflex response to lowering of cardiac output but occurred independently and presumably was a result of increased peripheral vascular resistance. Vismara et al. (1975) have shown that disopyramide directly increased vascular resistance. As expected, increase in afterload raised the peak ventricular and aortic pressure and decreased the peak flow (Milnor, 1975) .
Most haemodynamic studies agree that disopyramide is a negative inotropic agent (Jensen et al., 1975; Hulting and Rosenhamer, 1975; Marrot et al., 1976) . This was confirmed in our study where max. dPower/dT was reduced by 12 per cent and cardiac output by per cent at one minute after the onset of infusion of the drug. Though cardiac output alone may be depressed by increases in afterload, max. dPower/dT is not, being independant of afterload (Stein and Sabbah, 1976) , confirming that disopyramide has a negative inotropic action. Significant depression of max. dPower/dT was shortlived and the reduction in cardiac output was less than 10 per cent after 15 minutes. Hence the negative inotropic action of disopyramide is transient, and progressively diminishes in intensity.
In most studies there has been no significant change in heart rate in patients in sinus rhythm (Jensen et al., 1975; Hillis et al., 1976; Marrot et al., 1976) . This was found in our study as well. Since disopyramide is known to have weak anticholinergic properties (Baines et al., 1976; McHaffie et al., 1977) some increase in heart rate might be expected. However, the early increase in systolic impedance and systemic blood pressure would reflexly slow the heart. It is possible that this, perhaps coupled with the membrane stabilising effect of the drug (Reid and Williams, 1977) , would oppose the vagolytic effect and result in no change in heart rate.
Finally, our results of DPTI/TTI show that there is no deterioration in subendocardial blood flow after disopyramide administration. At all times after disopyramide there was an increase in the ratio, varying from 3 to 6 per cent, though this was not statistically significant. This is of considerable benefit when disopyramide is given to patients with anaemia, aortic valve disease, coronary atherosclerosis, acute myocardial infarction, or after cardiac surgery. All these conditions are known to be associated with impairment of blood supply to the subendocardial region (Hoffman and Buckberg, 1975) . We wish to point out that in our study the ratio DPTI/TTI has been derived by assuming that recorded peripheral arterial pressure waveform during systole is identical in pressure values at every instant with the pressure waveform in the aorta and left ventricle, and that the mean left atrial pressure is a valid approximation to left ventricular enddiastolic pressure.
We have thus shown that disopyramide has a brief negative inotropic action, that it increases peripheral arterial resistance for at least 30 minutes, and that it does not reduce subendocardial blood flow. 
